KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Mogamulizumab was one of the first new CTCL treatments and many others are being studied, such as monoclonal antibodies KIR3DL2 (lacutamab) [24], anti-PD1 (pembrolizumab, nivolumab) [25,26], anti-PDL1 (atézolizumab), anti-CD47 [27], and anti-CD70 [28,29].